Experts in healthcare reimbursement and regulation,
providing customized consulting
and education services.

Training Programs

We bring the experts to you with a range of on-site education options and bootcamp style programs that teach how a firm grasp of the rules leads to operational excellence.

More information »

Audits & Assessments

Our team of specialized regulatory specialists can assist your organization in revving up your revenue cycle by auditing and assessing key processes for coding and billing.

More information »

Regulatory Monitoring

Our team is available for ongoing regulatory watchdog services that answer your questions and offer you the latest Medicare news, analysis and operational guidance.

More information »

Oct
28

October 20-27 CMS Transmittals and MLN Matters articles

Email This Post Print This Post

CMS revises list of compendia for use in determining a “medically accepted indication” of drugs and biologicals used off-label in anti-cancer chemotherapeutic regimens

On October 24, CMS issued a transmittal recognizing four authoritative compendia for use in determining medically accepted indications for drugs and biologicals used in off-label anti-cancer chemotherapeutic regimens.

Effective date:
June 5, 2008 – NCCN Drugs and Biologics Compendium
June 10, 2008 – Thomson Micromedex DrugDex
July 2, 2008 – Clinical Pharmacology
Implementation Date: November 25, 2008

View the transmittal.

CMS updates common working file (CWF) edits for influenza virus vaccine and pneumococcal vaccine codes

On October 24, CMS updated its CWF edits to include influenza virus and pneumococcal vaccine CPT codes 90655, 90656, and 90669.

Effective date: April 6, 2009
Implementation date: April 6, 2009

View the transmittal.

CMS implements changes to interpretive guidelines for hospital conditions of participation

On October 17, CMS issued updated interpretative guidance for the hospital conditions of participation.

Effective date: Upon issuance
Implementation date: Upon issuance

View the transmittal.

Leave a Reply